SenzaGen AB

As of June 30, 2026, SenzaGen AB carries a market capitalization of 184.00M, placing it among publicly traded companies globally. Its enterprise value stands at 165.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SenzaGen AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, SenzaGen AB has 32.51M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.85, and the price-to-book ratio stands at 2.05.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 165.31M versus a market cap of 184.00M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SenzaGen AB maintains a current ratio of 2.90, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.72, indicating elevated leverage, while an interest coverage ratio of -8.80 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SenzaGen AB posted a negative return on equity (ROE) of -12.84, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.37, reflecting losses generated across the asset base. The company generates approximately 1.72M in revenue per employee across its workforce of 35.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.53 indicates how many times SenzaGen AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SenzaGen AB recorded an income tax benefit of -355,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -11.03M and -10.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, SenzaGen AB's stock has declined approximately 27.41% over the past 52 weeks. The 50-day moving average sits at 4.84, while the 200-day moving average is 5.30.

Over the twelve months ended June 30, 2026, SenzaGen AB generated 61.05M in revenue and converted that into -10.67M in net income, yielding earnings per share of -0.35. EBITDA reached -10.85M, while operating income came in at -8.82M.

As of June 30, 2026, SenzaGen AB holds 35.52M in cash and equivalents against 16.83M in total debt, resulting in a net debt position of -31.14M. Total book value stands at 89.88M, with working capital of 39.62M providing operational flexibility.

SenzaGen AB produced -5.92M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, SenzaGen AB posted a gross margin of 64.04, reflecting its pricing power and cost economics. The operating margin of -14.45 and net profit margin of -17.48 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.76, meaning SenzaGen AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SenzaGen AB's most recent stock split took place on November 18, 2019 with a 281:288 split ratio.

As of June 30, 2026, SenzaGen AB has an Altman Z-Score of 0.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.